{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:18:00Z","timestamp":1768439880638,"version":"3.49.0"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s177324","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T20:33:33Z","timestamp":1541018013000},"page":"705-713","source":"Crossref","is-referenced-by-count":10,"title":["Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia"],"prefix":"10.2147","volume":"Volume 10","author":[{"given":"Gabriel","family":"Tremblay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Dolph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7014-4104","authenticated-orcid":true,"given":"Menaka","family":"Bhor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qayyim","family":"Said","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-0159","authenticated-orcid":true,"given":"Brian","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-1997","authenticated-orcid":true,"given":"Andrew","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,11]]},"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=45833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=45833","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T20:33:34Z","timestamp":1541018014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/cost-consequence-model-comparing-eltrombopag-versus-romiplostim-for-ad-peer-reviewed-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/ceor.s177324","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}